NATROX® US Randomized Control Trial (RCT) submitted for publication

Principal investigator, Thomas Serena MD has submitted a manuscript detailing the efficacy of NATROX® Oxygen Wound Therapy in a randomised control trial (RCT). The trial focused on non-healing diabetic foot ulcers (DFUs) and primarily evaluated the impact of continuous topical oxygen on healing outcomes when compared to best practice standard of care. With well over 100 patients completing the full 12 week therapy period, this study is expected to become a key paper supporting the use of continuous topical oxygen therapy in non-healing DFUs.

Dr Serena commented, “the speed of recruitment and completion of the clinical trial by the study sites has been unprecedented, despite the Covid-19 pandemic. There is a clear clinical need for continuous topical oxygen therapy in chronic wound care.”

The NATROX® US RCT article will be published in the upcoming weeks. If you would like to be one of the first to get a copy of the paper, please email us at or keep an eye on our Website and LinkedIn page.